RESEARCH ARTICLE

Prevalence and determinants of peripheral arterial disease in children with nephrotic syndrome

Gbenga Akinyosoye1*, Adaobi U. Solarin1,2, Adeyemi Dada3, Motunrayo O. Adekunle1, Alaba B. Oladimeji1, Adeola O. Owolabi1, Clement M. Akinsola4, Barakat A. Animasahun1,2, Fidelis O. Njokanma1,2

1 Department of Paediatrics, Lagos State University Teaching Hospital, Lagos, Nigeria, 2 Department of Paediatrics and Child Health, Lagos State University College of Medicine, Lagos, Nigeria, 3 Department of Chemical Pathology, Lagos State University College of Medicine, Lagos, Nigeria, 4 Department of Community and Primary Health Care, University of Lagos, Lagos, Nigeria

* gbengayosoye@yahoo.com

Abstract

Peripheral arterial disease (PAD) is the least studied complication of nephrotic syndrome (NS). Risk factors which predispose children with NS to developing PAD include hyperlipidaemia, hypertension and prolonged use of steroids. The development of PAD significantly increases the morbidity and mortality associated with NS as such children are prone to sudden cardiac death. The ankle brachial index (ABI) is a tool that has been proven to have high specificity and sensitivity in detecting PAD even in asymptomatic individuals. We aimed to determine the prevalence of PAD in children with NS and to identify risk factors that can independently predict its development. A comparative cross-sectional study was conducted involving 200 subjects (100 with NS and 100 apparently healthy comparative subjects that were matched for age, sex and socioeconomic class). Systolic blood pressures were measured in all limbs using the pocket Doppler machine (Norton Doppler scan machine). ABI was calculated as a ratio of ankle to arm systolic blood pressure. PAD was defined as ABI less than 0.9. The prevalence of PAD was significantly higher in children with NS than matched comparison group (44.0% vs 6.0%, p < 0.001). Average values of waist and hip circumference were significantly higher in subjects with PAD than those without PAD (61.68 ± 9.1cm and 67.6 ± 11.2 cm vs 57.03 ± 8.3cm and 65.60 ± 12.5cm respectively, p < 0.005). Serum lipids (triglyceride, very low density lipoprotein, total cholesterol and low density lipoprotein) were also significantly higher in subjects with PAD than those without PAD [106.65mg/dl (67.8–136.7) vs 45.72mg/dl (37.7–61.3), 21.33mg/dl (13.6–27.3) vs 9.14mg/dl (7.5–12.3), 164.43mg/dl (136.1–259.6) vs 120.72mg/dl (111.1–142.1) and 93.29mg/dl (63.5–157.3) vs 61.84mg/dl (32.6–83.1), respectively p < 0.05]. Increasing duration since diagnosis of NS, having a steroid resistant NS and increasing cumulative steroid dose were independent predictors of PAD in children with NS; p < 0.05 respectively. With these findings, it is recommended that screening for PAD in children with NS should be done to prevent cardiovascular complications before they arise.
Introduction

Nephrotic syndrome (NS) remains the most common manifestation of glomerular disease in childhood [1–3]. It is defined by massive proteinuria, hypoalbuminaemia, generalized oedema and hyperlipidaemia [4]. Most studies estimate the global incidence of NS to be 2 to 7 per 100,000 population with a prevalence of 16 per 100,000 population [3–5]. Children with NS are at increased risk of complications such as infections, acute kidney injury, thromboembolism and peripheral arterial disease (PAD) [5, 6]. However, of these complications, PAD remains the least studied, especially in children. Peripheral arterial disease is an umbrella term used to describe a group of disorders that result in structural and functional alteration of arteries supplying blood to the viscera and limbs. It is a circulatory problem in which narrowed arteries from widespread accumulation of fatty deposits reduce blood flow to the heart, brain, and legs [7]. Peripheral arterial disease has been established to be prevalent among children with chronic kidney disease, especially children with NS, with a prevalence as high as 80% documented in Egypt by Mohammed et al. [4] The development of PAD can become progressive and associated with a significant increase in cardiovascular related events like cardiac arrest, arrhythmias, transient ischaemic attack and sudden cardiac death that can occur in children [8, 9].

There is paucity of data on the burden of PAD in children with NS, with the few studies reporting a high prevalence of PAD, above 80% [4, 8]. Thus, with a prevalence of PAD in children with NS as high as 80% compared to 9% in apparently healthy controls in an African study done in Egypt by Mohammed et al. [4] the need for prompt screening of children with NS for PAD cannot be overemphasized. Furthermore, children with NS who develop PAD generally have a worse outcome and survival than those without PAD [10].

Nephrotic syndrome is associated with hyperlipidaemia which predisposes to PAD through endothelial dysfunction as well as inflammation [8, 11]. High levels of lipid in the blood promote plaque formation which can accumulate in the arteries and cause narrowing of the lumen of these arteries and thus limit blood flow. Other factors that contribute to the development of PAD in children with NS include hypertension, prolonged use of steroids, uncontrolled hyperglycaemia and proteinuria [4, 12]. These risk factors are associated with NS and its treatment, and can lead to the development of PAD by causing endothelial damage. Children with NS and associated PAD are significantly at an increased risk of thromboembolic phenomena such as cerebrovascular accidents, compared to other children with NS who do not have PAD and to the general population [13].

Nephrotic syndrome coexisting with PAD is also a known risk factor for myocardial infarction in adulthood, hence children with the co-morbidity are likely to develop adverse cardiovascular events at a relatively young age compared to their healthy counterparts [14, 15]. One consistent risk factor from previous studies for the development of PAD is atherosclerosis [9, 16–20]. Hyperlipidaemia is a known risk factor for the development of atherosclerosis, and is a major component of NS that predisposes to vascular damage and, as a result, poses a risk for the development of PAD, particularly in children with NS [8, 11]. A valid and reliable screening tool in detecting PAD is the ankle brachial index (ABI). The ABI is proven to be a sensitive, non-invasive, user friendly, readily available, and cost-effective screening tool for PAD that has also been validated for use in children [4, 21]. The ABI is defined as the ratio of systolic blood pressure measured at the ankle to that measured at the brachial artery [22]. Normal values for ABI in adults and children are between 0.9 and 1.3 [21]. An abnormal value below 0.9 is a powerful independent marker of cardiovascular risk, especially atherosclerosis [20, 23]. A three-to-four-fold increase in cardiac associated mortalities arises when the ABI value is less than 0.9 [23]. Apart from its ability to detect the presence of PAD, it also helps in
prognosticating cardiovascular events and functional impairments even in the absence of symptoms [23–25]. Studies have consistently shown the ABI to have a minimum sensitivity and specificity of 90% and 98% respectively in predicting PAD, and with a minimum positive predictive value and negative predictive value of 90% and 98.63% respectively [22–29].

We aimed to determine the burden of PAD in children with NS and identify factors that can independently predict the development of PAD.

Materials and methods

The study described in this report was carried out at the paediatric nephrology clinic of Lagos State University Teaching Hospital (LASUTH) Ikeja, a tertiary centre that receives referrals from all parts of Lagos state and environs. Lagos is a metropolitan state with a heterogeneous population, situated in the coastal region of South-Western Nigeria. It has a population of about 9 million people, according to the last national population census carried out in 2006, and it was projected to have increased to over 12 million by 2016 [30]. Though Lagos is cosmopolitan, the majority of its inhabitants are Yorubas. The paediatric nephrology clinic of LASUTH runs on a weekly basis and attends to diverse cases. On average, about eight patients with nephrotic syndrome are seen per week, most of them being follow up cases. However, some patients with acute complaints are admitted to the ward via the paediatric emergency unit.

Study design

This was a comparative cross-sectional study involving children with NS as well as age, sex and socioeconomic class matched apparently healthy participants in the comparison group. A group matching was done after recruitment of the cases.

Study population

This comprised 100 patients with idiopathic NS, who were recruited consecutively and aged one to fifteen years attending the Paediatric Nephrology Clinic of LASUTH. Hundred apparently healthy children with no history of renal, haematological and cardiovascular diseases were matched for age, sex and social class to serve as comparison group. The participants in the comparative group were recruited from the paediatric out-patient department, the immunization clinic of LASUTH, children attending specialist clinics such as the dermatology clinic for follow up and teenage children presenting for medical fitness for school resumption.

Inclusion criteria

All children with a diagnosis of idiopathic NS aged 1 to 15 years were recruited as the cases and the comparative group had children aged 1 to 15 years with no fever or acute illness.

Exclusion criteria

For the cases, children with diabetes mellitus, sickle cell anaemia, underlying cardiac abnormalities and previous renal abnormalities other than NS were excluded. In the comparison group, in addition to these, children with fever, asthma, proteinuria greater than 1+, obese children and those on steroids were excluded.

Data collection procedures

The researchers obtained data from all participants using a self-pre-designed proforma. The proforma included sections for the participants bio-data (age, sex and ethnic group), date of
diagnosis of NS, presence of any other chronic illness e.g., cardiac or, renal disease, sickle cell anaemia, etc. Social history of passive smoking, socio economic status and family history of cardiac and renal diseases were obtained. Use and duration of medications especially steroids and anti-hypertensives were documented. The medical records of participants were also checked to ascertain the cumulative dose of steroid used and identify those who have had a renal biopsy. Their response to steroid was documented from the case note into steroid sensitive (remission achieved with steroid therapy alone) [31], steroid dependent (two consecutive relapses occurring during corticosteroids tapering or within fourteen days of its cessation) [31, 32] and steroid resistant (failure to achieve response in spite of eight weeks of oral prednisolone at 60mg/m²/day) [31, 32]. Each participant had a general physical examination done to rule out any asymptomatic abnormality for example, a cardiac murmur.

Ankle brachial index

Was measured using appropriate blood pressure cuffs (bladder width at least 40% of the limb circumference, length encircling 80% to 100% of the limb circumference) and pocket doppler probe electronics [24, 33]. Subjects were positioned supine for 5 minutes [24]. The pressures were taken prior to any invasive procedure. The systolic blood pressure at the brachial artery of each arm, the posterior tibial artery and dorsalis pedis artery sof each ankle were measured. The higher of the two upper limb pressures and of the lower limb pressures were used to calculate the ABI. The ratio of the systolic ankle pressure to the systolic brachial pressure gives the ABI [33]. ABI was classified as low (< 0.9), normal (0.9–1.3), and high (> 1.3) [4, 34, 35]. The following steps were taken by the investigators in performing the ABI measurement using the pocket doppler.

1. Following explanation of the procedure, the participant was made to lie supine for five minutes in a quiet room, removing socks, shoes and tight clothing.
2. The pocket doppler was assembled and the investigator donned on clean gloves.
3. An appropriate sized blood pressure cuff was tied on the upper arm approximately one to two centimetres above the ante-cubital fossa.
4. The brachial pulse was identified and gel was applied over the pulsation.
5. Doppler was turned on and the probe was held at 45 degree angle towards the blood flow.
6. The probe was moved slowly through the gel in circular motion until a pulse sound was heard.
7. The blood pressure cuff was inflated until the pulse sound disappeared. It was then further inflated by 10-20mmHg.
8. The cuff was gradually deflated until the arterial sound returned. The pressure at which the sound returned was noted and the cuff completely deflated.
9. Steps 3–7 were repeated on the other arm. The higher reading of the two systolic arm pressures was used to calculate the ABI.
10. The dorsalis pedis and posterior tibial pulsations were identified. With a similar method outlined in steps 3–7, the doppler machine was used to determine the systolic blood pressures. The highest reading of the four systolic pulses was used to calculate the ABI.
11. Gel was cleaned off the subject.
12. ABI was calculated as the highest of the four systolic pressures from the two ankles divided by the higher of the two brachial pressures and the value documented.

13. The participant was thanked and assisted to dress up.

**Blood and urine samples collection**

Five millilitres (5mls) of blood for serum protein, albumin and non fasting lipid profile was collected in a lithium heparin bottle. A drop of blood was put on the blood glucose meter to check for the random blood glucose which was subsequently recorded. Freshly voided urine was collected in a universal bottle and urinalysis was done using Siemens urinalysis strips Combi-9 with the remaining urine sample analysed for protein and creatinine to determine a spot protein-creatinine ratio.

**Biochemical analysis**

Blood and urine samples were collected by the researchers and transported immediately to the research laboratory. The blood samples were immediately centrifuged by the researcher and stored. Analysis of the samples were done by the chemical pathologist and assisted by the researchers. Blood samples were centrifuged at 350 revolutions per minute (rpm) for 5 minutes; and the serum separated and stored at a temperature of (-20˚C) in a refrigerator until each batch of samples were collected and afterwards analysed. Lagos State University Teaching Hospital (LASUTH) enjoys un-interrupted power supply largely from the independent power project (IPP) situated in Alausa, Ikeja and therefore maintenance of sample at required temperature expected was achieved.

Serum cholesterol was analysed using enzymatic (Cholesterol oxidase) colorimetric method [36]. Serum triglyceride was analysed using enzymatic (glycerol kinase) colorimetric method [37]. Total serum protein was analysed using the Biuret method. Serum albumin was analysed using colorimetric method (Bromocresol Green).

Siemens (Combi-9) urinary test strips was used for urinalysis assessment. Urine protein was analysed using colorimetric method (Pyrogallol Red).

**Data analysis**

Data was analysed using Microsoft Excel and Statistical Package for Social Sciences (SPSS) version 24.0 (IBM, Inc, Chicago, Illinios USA). Demography of participants were presented as frequency and percentages. Tables and figures were used to present the variables as appropriate. Social class of participants was classified into upper, middle and lower using Ogunlesi social classification [38].

Bar chart was used to present prevalence of peripheral arterial disease (which is the dependent variable/outcome) among patients with NS and the comparison group. Fisher’s exact test was used to compare prevalence of PAD between the two groups. Association between categorical independent variables (sex, socio-economic class, age group, BMI for age Z score categories) and outcome variable (PAD) was assessed using Pearson’s chi square or Fisher’s exact test for expected frequencies less than five.

For numeric independent variables (e.g. weight, blood pressure, lipid profile, random blood glucose), Kolmogorov-Smirnov test was used to assess data normality. Independent student t-test was used to compare means according to the presence or absence of PAD when normally distributed. Mann Whitney U test was used for comparison of the median values of two groups when data were skewed (not normally distributed).
Multiple logistic regression, a form of multi-variate analysis was used to determine independent predictors of PAD among NS participants among a list of covariates (socio-demographics, clinical and biochemical parameters). Probability (p) value was considered significant at less than 0.05 and at a confidence interval of 95%.

Ethical approval

Approval was granted by the Health and Research Ethics committee of LASUTH with approval number LREC/06/10/1173. The personal details of the patients were used in a non-identifiable and confidential manner. Written informed consent was obtained from the caregivers and in addition assent from children seven years and above.

Results

Demographic, clinical and laboratory characteristics

One hundred (100) children aged 1–15 years with idiopathic NS and 100 age, sex and social class matched comparison group were recruited for the study. The mean age for participants with nephrotic syndrome and the comparison group were 7.53 ± 2.6 years and 7.07 ± 2.6 years, respectively. The predominant age group was 6 to 10 years. Hip circumference, weight for age z score (WAZ) height for age z score (HAZ), and body mass index for age z score (BAZ) were comparable between the two groups (p>0.05). Waist circumference, waist hip ratio and lipid profile indices were significantly higher among children with NS than the comparison group. Four fifth of all the NS children were steroid sensitive. Average duration since diagnosis of NS was 2 years with a median cumulative steroid dose of about 4000mg as shown in Table 1.

The mean systolic ankle pressure was significantly lower in cases than the comparative group (p < 0.001) whereas mean systolic brachial pressure was comparable between both groups (p = 0.193). ABI was significantly lower in nephrotic syndrome patients than the comparative group (p < 0.001). Table 2. Forty-four of hundred NS patients had peripheral arterial disease (ABI range 0.7–0.8) giving a prevalence rate of 44%.–Fig 1. The corresponding figures for the comparative group were six of hundred subjects with a prevalence rate of 6.0%. Thus the prevalence of PAD was significantly higher in participants with NS (p < 0.001). There is about 12 fold (95% CI = 3.712–35.312) odds of developing PAD in participants with NS as compared to the comparative group.

The proportion of children with PAD was highest among the age group of 11–15 years. The occurrence of PAD did not differ significantly across gender and socio-economic status in participants with NS. Participants with PAD have significant higher waist circumference, hip circumference and lipid profiles than those without PAD. Duration since diagnosis, cumulative steroid dose and duration of steroid use were higher among participants with PAD (p < 0.05) as shown in Table 3.

Table 4 shows the result of a multiple logistic regression model that was developed to identify independent predictors of peripheral arterial disease. Increasing duration since diagnosis of NS (AOR = 4.372; 95% CI = 2.934–12.301), steroid resistance (AOR = 12.546; 95% CI = 3.280–47.992) and increasing cumulative steroid dose (AOR = 1.434; 95% CI = 1.083–1.902) are independent predictor of PAD.

Discussion

The present study among children with idiopathic NS demonstrates a high prevalence of PAD, one of the least studied but potentially fatal complication of NS. Children with NS have about
twelve fold odds of developing PAD than children without NS. This pattern was more prominent in those with steroid resistant NS than those responsive to steroid. High rate of PAD in children with steroid resistant NS has been previously documented by Mohammed et al. [4]. The higher risk of PAD in steroid resistant NS may be attributed to persistence of proteinuria and progression to chronic kidney disease which is an established risk factor for PAD [8, 38]. Chronic kidney disease leads to development of PAD through persistent proteinuria, endothelial dysfunction and chronic inflammatory state thereby enhancing plaque formation in the lumen of vessels [12].

In the current study occurrence of PAD was found to increase with age albeit not statistically significant. The few earlier studies in children with NS did not check for association of age with PAD. The finding of PAD occurring more among the older age subjects with NS in

| Variables                       | Case (n = 100) n (%) | Comparative group (n = 100) n (%) | Total       | χ²   | p-value |
|--------------------------------|---------------------|----------------------------------|-------------|------|---------|
| Age group (Years)              |                     |                                  |             |      |         |
| 1–5                            | 26(26.0)            | 26(26.0)                         | 52(26.0)    | 0.000| 1.000   |
| 6–10                           | 44(44.0)            | 44(44.0)                         | 88(44.0)    |      |         |
| 11–15                          | 30(30.0)            | 30(30.0)                         | 60(30.0)    |      |         |
| Mean ± SD                      | 7.53±2.6            | 7.07±2.6                         | 7.30±2.6**  | 0.902| 0.368   |
| Gender                         |                     |                                  |             |      |         |
| Male                           | 58(58.0)            | 58(58.0)                         | 116(58.0)   | 0.000| 1.000   |
| Female                         | 42(42.0)            | 42(42.0)                         | 84(42.0)    |      |         |
| Social class                   |                     |                                  |             |      |         |
| Lower                          | 41(41.0)            | 41(41.0)                         | 82(41.0)    | 0.000| 1.000   |
| Middle                         | 36(36.0)            | 36(36.0)                         | 72(36.0)    |      |         |
| Upper                          | 23(23.0)            | 23(23.0)                         | 46(23.0)    |      |         |
| Waist circumference            | 61.68±9.1           | 57.03±8.3                        | 59.36±9.0*  | 0.902| <0.001* |
| Hip circumference              | 67.65±11.2          | 65.60±12.5                       | 66.63±11.9**| 3.766| 0.224   |
| Waist hip ratio                | 0.37±1.3            | 0.32±1.1                         | 0.89±0.1**  | 1.221| <0.001* |
| WAZ                            | 0.37±1.3            | 0.32±1.1                         | 0.35±1.2**  | 3.842| 0.831   |
| HAZ                            | -1.06±1.3           | -0.77±1.2                        | -0.91±1.3** | 1.373| 0.172   |
| Waist hip ratio                | 1.27±1.3            | 1.02±1.1                         | 1.15±1.2**  | 1.204| 0.231   |
| RBG (mg/dl)                    | 85.71±17.1          | 86.87±19.5                       | 86.29±18.3* | -0.447| 0.656   |
| Serum protein (mg/dl)          | 5.30±1.0            | 7.09±1.0                         | 6.20±1.3**  | 12.706| <0.001* |
| Albumin (mg/dl)                | 3.45±0.9            | 4.63±0.5                         | 4.04±0.9*   | 11.242| <0.001* |
| Triglyceride (mg/dl)           | 106.7 (67–137)      | 45.7 (38–61)                     | 63.7(42–115)| -5.122| <0.001* |
| VLDL (mg/dl)                   | 21.3(14–27)         | 9.1(8–12)                        | 12.5(8–22)  | -4.848| <0.001* |
| TC (mg/dl)                     | 164.4(136–259)      | 120.7 (111–142)                  | 139(113–169)| -4.534| <0.001* |
| LDL (mg/dl)                    | 93.3 (63–157)       | 61.8(32–83)                      | 72.6(44–111)| -4.242| <0.001* |
| Duration since diagnosis (Months) | 24.0(12.51)       | NA                               | NA          |      |         |
| Cumulative steroid dose (mg)   | 4165(3162–5280)     | NA                               | NA          |      |         |
| Duration of steroid use (months) | 12.0 (10.0–36.0)   | NA                               | NA          |      |         |
| Response to steroid            |                     |                                  |             |      |         |
| Steroid dependent              | 3(3.0)              | NA                               | NA          |      |         |
| Steroid resistance             | 17(17.0)            | NA                               | NA          |      |         |
| Steroid sensitive              | 80(80.0)            | NA                               | NA          |      |         |

χ²—chi square **Independent student t test; WAZ: Weight for age z score, HAZ: Height for age z score, BAZ: Body mass index for age z score, RBG: Random blood glucose, VLDL: Very low density lipoprotein, TC: Total cholesterol, LDL: Low density lipoprotein

https://doi.org/10.1371/journal.pone.0266432.t001
Table 2. Mean ABI in cases and comparison group.

| Variables               | Case (n = 100) Mean ± SD | Comparison group (n = 100) Mean ± SD | t-value | p-value |
|-------------------------|--------------------------|-------------------------------------|---------|---------|
| **Systolic ankle pressure** |                          |                                     |         |         |
| Mean ± SD               | 90.7 ± 24.4              | 102.7 ± 24.4                        | 6.421   | < 0.001*|
| Range                   | 70.0–130.0               | 70.0–130.0                          |         |         |
| **Systolic brachial pressure** |                      |                                     |         |         |
| Mean ± SD               | 102.2 ± 26.3             | 98.7 ± 22.2                         | 1.832   | 0.193   |
| Range                   | 70.0–125.0               | 70.0–130.0                          |         |         |
| **Ankle brachial index** |                          |                                     |         |         |
| Mean ± SD               | 0.92 ± 0.16              | 1.03 ± 0.12                         | 4.945   | < 0.001*|
| Range                   | 0.7–1.3                  | 0.8–1.3                             |         |         |

χ² = 38.507, p < 0.001

Fig 1. Prevalence of PAD in children with nephrotic syndrome compared with an apparently healthy comparative group. Forty-four of hundred NS patients had peripheral arterial disease (ABI range 0.7–0.8) giving a prevalence rate of 44%. Fig 1. The corresponding figures for the comparative group were six of hundred subjects with a prevalence rate of 6.0%. Thus the prevalence of PAD was significantly higher in participants with NS (p < 0.001).

https://doi.org/10.1371/journal.pone.0266432.g001
the current study is consistent with earlier reports in adults [10, 16, 39]. Changes in the structure and functions of large and small arteries with resultant loss of compliance in the vasculature increases with age [40]. The loss of compliance of these vessels encourages endothelial damage and plaque accumulation with resultant peripheral arterial disease [16].

The majority of subjects with NS recruited in the current study were from the low social class as compared to the middle and upper class (41%, 36% and 23% respectively). This is consistent with findings from other African countries and Europe [4, 15, 41]. However, the proportion of children with PAD in the same cohort of NS subjects recruited was higher in the upper socio-economic group in the present study. This contrasts findings in the literature from developed countries where PAD was more common among the low socio-economic class [42]. The reason for this finding may be attributed to the fact that children from the higher social class in our environment are more likely to live a sedentary lifestyle with a high

| Variables                  | PAD (n = 44) n (%) | No PAD (n = 56) n (%) | χ²   | p-value |
|----------------------------|-------------------|----------------------|------|---------|
| **Age group (Years)**      |                   |                      |      |         |
| 1–5                        | 9(34.6)           | 17(65.4)             | 2.002 | 0.368   |
| 6–10                       | 19(43.2)          | 25(56.8)             |      |         |
| 11–15                      | 16(53.3)          | 14(46.7)             |      |         |
| **Gender**                 |                   |                      |      |         |
| Male                       | 24(41.4)          | 34(58.6)             | 0.385 | 0.535   |
| Female                     | 20(47.6)          | 22(52.4)             |      |         |
| **Social class**           |                   |                      |      |         |
| Lower                      | 18(43.9)          | 23(56.1)             | 1.005 | 0.605   |
| Middle                     | 14(38.9)          | 22(61.1)             |      |         |
| Upper                      | 12(52.2)          | 11(47.8)             |      |         |
| **Waist circumference**    | 64.89±10.4        | 59.16±7.2            | 3.268 | 0.001*  |
| **Hip circumference**      | 70.89±12.9        | 65.10±8.9            | 2.653 | 0.009*  |
| **Waist hip ratio**        | 0.92±0.1          | 0.91±0.1             | 1.115 | 0.269   |
| **Hazard (HAZ)**           | -1.13±1.2         | -1.01±1.3            | -0.383 | 0.703  |
| **Body mass index (BAZ)**  | 1.57±1.2          | 1.06±1.4             | 1.568 | 0.121   |
| **Random blood glucose (RBG)** | 86.18±20.5       | 85.34±14.1           | -0.243 | 0.809  |
| **Serum protein (mg/dl)**  | 5.17±0.8          | 5.40±1.2             | -1.122 | 0.264  |
| **Albumin (mg/dl)**        | 3.53±0.9          | 3.39±0.9             | 0.785 | 0.435   |
| **Triglyceride (mg/dl)**   | 113.3 (82–157)    | 105.1 (59–132)       | -1.934 | 0.043*  |
| **VLDL (mg/dl)**           | 22.7 (16–31)      | 21.0 (12–26)         | -1.674 | 0.047*  |
| **TC (mg/dl)**             | 171.5 (146–269)   | 156.7 (117–206)      | -1.559 | 0.033*  |
| **LDL (mg/dl)**            | 110.3 (80–174)    | 80.8 (52–138)        | -2.024 | 0.043*  |
| **Duration since diagnosis** | 32.0 (21.5–58.5)  | 22.00 (11.0–48.0)    | -2.266 | 0.022*  |
| **Cumulative steroid dose (mg)** | 4605.0 (3775–7415) | 3675.0 (2925–4750)  | -3.320 | 0.001*  |
| **Duration of steroid use (months)** | 24.00 (11.0–48.0) | 12.00 (7.0–24.0)   | -2.095 | 0.036*  |
| **Response to steroid**    |                   |                      |      |         |
| Steroid dependent          | 2(66.7)           | 1(33.3)              | 17.537 | <0.001* |
| Steroid resistance         | 15(88.2)          | 2(11.8)              |      |         |
| Steroid sensitive          | 27(33.8)          | 53(56.0)             |      |         |

WAZ: Weight for age z score, HAZ: Height for age z score, BAZ: Body mass index for age z score, RBG: Random blood glucose, VLDL: Very low density lipoprotein, TC: Total cholesterol, LDL: Low density lipoprotein

https://doi.org/10.1371/journal.pone.0266432.t003
tendency for development of obesity. Also dietary intake of junks from affluence may be contributory.

In the current study, a significant proportion of children with PAD have had NS for more than twelve months. This finding is similar to what was found in Egypt among children with NS [4]. The duration of nephrotic hyperlipidaemia appears to be critical to initiating vascular and endothelial damage which favours influx of lipoprotein into the mesangium and ultimately leading to proliferation and sclerosis of the vessels. Lipoproteins are more elevated in children with long standing nephrotic syndrome than those who are recently diagnosed and thus increasing their risk for the development of peripheral arterial disease [4, 43]. Screening of children who have had active NS more than twelve months for PAD is thus highly recommended before they develop cardiovascular complications.

In our study, chronic use of steroids was significantly associated with PAD. This is in keeping with a study in France among similar population of subjects by Willenberg et al. [44] Steroids have been reported to increase arterial calcification and its association with distal occlusive pattern has been observed in patients with chronic kidney disease [44]. In addition, chronic use of steroids may result in the development of hypertension which is a risk factor for PAD [45]. Children with NS who have frequent relapses requiring chronic use of steroids and those who are dependent on steroids should have more frequent checks of their ABI to check for PAD.

One of our findings is that a significant number of subjects with PAD had a higher mean value of waist and hip circumference compared to subjects without PAD. This is difficult to compare with studies in children with NS as association with PAD was not checked in these studies. However the finding is similar to that of Martha et al. [46] and Umueri et al. [47] in adult subjects. Waist and hip circumference provides a unique indicator of body fat distribution in children [48]. It has been proven to be a surrogate marker of abdominal fat mass because it correlates well with subcutaneous and intra-abdominal fat mass [48]. Waist and hip circumference can identify patients who are at increased risk of obesity-related cardio-metabolic disease including PAD above and beyond the measurement of body mass index [48, 49]. Combined measurements of waist circumference, hip circumference and waist to hip ratio are reported to be better predictors of cardiovascular disease including PAD in children than body mass index [50]. Obesity has been linked closely with other risk factors for the development of

| Table 4. Independent predictors of peripheral arterial disease among patients with nephrotic syndrome. |
|---------------------------------|-----------------|-----------------|-----------------|
| Variables | AOR | 95% CI | p-value |
| Age | 0.973 | 0.943–1.004 | 0.083 |
| Gender: Female | 1.742 | 0.706–4.303 | 0.229 |
| Social class: Lower | 1.024 | 0.416–2.523 | 0.958 |
| Duration since diagnosis (months) | 4.372 | 2.934–12.301 | 0.021* |
| Response to steroid: Steroid resistance | 12.546 | 3.280–47.992 | < 0.001* |
| Cumulative steroid dose (mg) | 1.434 | 1.083–1.902 | 0.007* |
| Waist circumference (cm) | 1.225 | 0.951–1.577 | 0.116 |
| Hip circumference (cm) | 0.867 | 0.692–1.086 | 0.214 |
| Triglyceride (mg/dl) | 1.007 | 0.992–1.021 | 0.366 |
| VLDL (mg/dl) | 1.043 | 0.893–1.304 | 0.481 |
| TC (mg/dl) | 0.985 | 0.956–1.016 | 0.340 |
| LDL (mg/dl) | 1.015 | 0.985–1.045 | 0.328 |

VLDL: Very low density lipoprotein, TC: Total cholesterol, LDL: Low density lipoprotein

https://doi.org/10.1371/journal.pone.0266432.t004
PAD like hyperlipidaemia, hypertension and poor glycaemic control which could lead to endothelial dysfunction and ultimately PAD. Routine measurement of waist circumference, hip circumference and waist to hip ratio will be highly recommended for children with nephrotic syndrome during clinic visits to identify early deviation from normal.

The mean value of weight-for-age Z score was higher in the group with PAD than those without PAD in the current study. This finding may likely be due to the effect of prolonged use of steroids which is notorious for inducing hypercortisolism related side effects. High cortisol levels can lead to increased appetite, truncal fat accumulation, and altered lipid and glucose metabolism leading to obesity [50]. Similarly, the mean value of height-for-age Z score was lower in the group with PAD than in the group without PAD. This may also be due to the effect of prolonged steroid use. A comparable finding was reported by Simmonds et al. [51] among children with steroid dependent nephrotic syndrome. Steroids have inhibitory effects on growth hormone release. It also has direct effect on growth plate by suppressing chondrocyte proliferation, matrix proteoglycan synthesis and mineralization [51]. Moreover, persistence and or relapse of NS dictates continued use of steroids. Thus, simultaneously chronic disease state of NS may predispose to PAD and prolonged steroid use to impaired linear growth.

One of the findings of the present study is that the average values of serum lipids (total cholesterol, triglycerides, very low density lipoprotein and low density lipoprotein) were significantly higher in subjects with PAD than those without PAD. These results are in agreement with an Egyptian study also among children with NS [4]. Hyperlipidaemia increases the risk of premature atherosclerosis [4]. Infiltration and retention of low density lipoproteins in the arterial wall is a critical event that sparks an inflammatory response which results in the formation of plaques that leads to PAD [52]. The elevated average values of serum lipids in this current study is also consistent with findings in children and adults with nephrotic syndrome in Nigeria [53, 54]. Hyperlipidaemia in NS results from a compensatory response to reduced serum protein that leads to increased synthesis and decreased catabolism of lipids [33]. It is advocated that serum lipid profile of children with nephrotic syndrome be done routinely and more frequently in those who have frequent relapses and are steroid resistant.

In the present study, the mean values of both serum protein and albumin were lower in the subjects with peripheral arterial disease. This is comparable to findings in children and adults [4, 55]. With proteinuria and resultant hypoproteinaemia there is a compensatory hyperlipidaemia which can lead to endothelial damage and increase the risk of developing peripheral arterial disease.

In the current study, duration since diagnosis of nephrotic syndrome, steroid resistant nephrotic syndrome and cumulative dose of prednisolone greater than 3000mg were found to be independent predictors of peripheral arterial disease. Close monitoring of children with nephrotic syndrome with long duration since diagnosis and those with steroid resistant NS is important before they develop PAD. Prompt referral of children with NS who have abnormal ABI to the cardiologist for follow up is also advocated especially before they develop life threatening complications. With the documented high prevalence of PAD in children with NS, it is pertinent to screen for this condition before long term complications develop as they progress into adulthood.

Acknowledgments

The authors acknowledge Dr Ayo Faremi for his help with procuring some of the devices and accessories used for the study. Our thanks also goes to Drs Mariam Disu, Amontunur Lamina, Oluwabukola Kuti, Ibukunoluwa Adeboye and Tracy Ossai for their help with sample and
data collection. The amiable and enthusiastic subjects along with their parents/guardians who participated in the study are specially appreciated.

**Author Contributions**

**Conceptualization:** Gbenga Akinyosoye, Adaobi U. Solarin.

**Data curation:** Gbenga Akinyosoye, Adaobi U. Solarin, Adeyemi Dada, Alaba B. Oladimeji, Clement M. Akinsola, Barakat A. Animasahun, Fidelis O. Njokanma.

**Formal analysis:** Gbenga Akinyosoye, Adaobi U. Solarin, Adeyemi Dada, Motunrayo O. Adekunle, Alaba B. Oladimeji, Clement M. Akinsola, Barakat A. Animasahun, Fidelis O. Njokanma.

**Investigation:** Gbenga Akinyosoye, Adeyemi Dada, Motunrayo O. Adekunle, Alaba B. Oladimeji, Adeola O. Owolabi.

**Methodology:** Gbenga Akinyosoye, Adaobi U. Solarin, Alaba B. Oladimeji, Adeola O. Owolabi, Clement M. Akinsola, Barakat A. Animasahun, Fidelis O. Njokanma.

**Project administration:** Gbenga Akinyosoye, Adaobi U. Solarin.

**Resources:** Gbenga Akinyosoye, Adeyemi Dada, Adeola O. Owolabi.

**Supervision:** Gbenga Akinyosoye, Adaobi U. Solarin, Adeyemi Dada, Motunrayo O. Adekunle, Alaba B. Oladimeji, Barakat A. Animasahun, Fidelis O. Njokanma.

**Validation:** Gbenga Akinyosoye, Adaobi U. Solarin, Motunrayo O. Adekunle, Alaba B. Oladimeji, Adeola O. Owolabi, Clement M. Akinsola, Barakat A. Animasahun.

**Writing – original draft:** Gbenga Akinyosoye, Adaobi U. Solarin, Motunrayo O. Adekunle, Alaba B. Oladimeji, Barakat A. Animasahun, Fidelis O. Njokanma.

**Writing – review & editing:** Gbenga Akinyosoye, Adaobi U. Solarin, Adeyemi Dada, Motunrayo O. Adekunle, Alaba B. Oladimeji, Adeola O. Owolabi, Clement M. Akinsola, Barakat A. Animasahun, Fidelis O. Njokanma.

**References**

1. Uwaezuoke SN. Steroid sensitive nephrotic syndrome in children: Triggers of relapse and evolving hypotheses on pathogenesis. Ital J Pediatr 2015; 41(1):1–6.
2. Inamdar P, Patil M, Majeeb A. Spectrum of renal biopsy findings in idiopathic nephrotic syndrome in children: An 18 months retrospective analysis at a tertiary care pediatric nephrology center in North Karnataka, India. J Sci Soc 2017; 44(5):80–82.
3. Ladapo TA, Esezobor CI, Lesi FE. Pediatric kidney diseases in an African country: Prevalence, spectrum and outcome. Saudi J Kidney Dis Transpl 2014; 25(5):1110–1116. https://doi.org/10.4103/1319-2442.139976 PMID: 25193924
4. Mohamed SM, Elmazary A, Taha HT. Ankle brachial index in children with steroid-resistant nephrotic syndrome. Sultan Qaboos Univ Med J 2013; 13(1):88–92. https://doi.org/10.12816/0003200 PMID: 23573387
5. Gbadegesin R, Smoyer WE. Comprehensive Pediatric Nephrology: Nephrotic Syndrome. Denis F, Franz S, editors. Philadelphia: Elsevier Inc 2008; 205–218.
6. Ibadin MO, Abiodun PO. Epidemiology and clinicopathologic characteristics of childhood nephrotic syndrome in Benin City, Nigeria. J Pak Med Assoc 1998; 48(8):235–238. PMID: 10067038
7. Natha B. Screening for peripheral arterial disease. South African Med J 2014; 104(2):148–152.
8. Patnaik SK, Kumar P, Bamal M, Patel S, Yadav MP, Kumar V, et al. Cardiovascular outcomes of nephrotic syndrome in childhood (CVONS) study: A protocol for prospective cohort study. BMC Nephrol 2018; 19(81):1–10. https://doi.org/10.1186/s12882-018-0878-9 PMID: 29614967
9. Ordorez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44(3):638–642. https://doi.org/10.1038/ki.1993.292 PMID: 8231039

10. Norman PE, Eikelboom JW, Graeme JH. Peripheral arterial disease: Prognostic significance and prevention of atherothrombotic complications. Med J Aust 2004; 181(3):150–154. https://doi.org/10.5694/j.mja181-060206 x PMID: 15287833

11. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE, Katz H, Dischvyer D. Dyslipidemia in nephrotic syndrome, mechanisms and treatment. Nat Rev Nephrol 2018; 14(1):57–70. https://doi.org/10.1038/nrneph.2017.155 PMID: 29176657

12. Singal K, Singal N, Gulupta P, Jagdish H, Rampal S. The prevalence of peripheral artery disease using ankle brachial index in hypertensive patients. Bangladesh J Med Sci 2016; 15(04):19–25.

13. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J. Lipids 2015; 7(9):14–53. https://doi.org/10.1155/2015/971453 PMID: 25949827

14. Xie L, Tang Y, Liu J, He S, Li J, Zhu Y, et al. Acute myocardial infarction in patients with nephrotic syndrome: a case series. J Geriatr Cardiol 2017; 14(1):481–484. https://doi.org/10.11909/j.issn.1671-5411.2017.07.009 PMID: 28868077

15. Hoppi L, Gilboa N, Kurland G, Weichler N, Orchard TJ. Pediatric Nephrology. Pediatr Nephrol 1994; 8(1):290–294.

16. Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int J Mol Sci 2015; 16(1):11294–11322. https://doi.org/10.3390/ijms160511294 PMID: 25993296

17. Boyko EJ, Monteiro-soares M, Wheeler SGB. Peripheral arterial disease, foot ulcers, lower extremity amputations and diabetes. Diabetes in America, 3rd edition 2015; 4(1):1–34.

18. Benetos A, Waebber B, Izzo J, Mitchell G, Resnick L, Asmar R, et al. Influence of age, risk factors of cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 2002; 15(12):1101–1108. https://doi.org/10.1016/s0895-7061(02)03029-7 PMID: 12460708

19. Jaffery Z, Greenbaum AB, Siddiqui MF, Gupta V, Mokkala V, et al. Predictors of mortality in patients with lower extremity peripheral arterial disease: five year follow-up. J Interv Cardiol 2009; 22(6):564–571. https://doi.org/10.1111/j.1540-8183.2009.00505.x PMID: 19780889

20. Xu D, Li J, Zou L, Xu Y, Hu D, Pagoto SL, et al. Sensitivity and specificity of the ankle–brachial index to diagnose peripheral artery disease: a structured review. Vasc Med 2010; 15(5):261–369.

21. Khan TH, Farooqui FA, Niaz K. Critical review of the ankle brachial index. Curr Cardiol Rev 2008; 4(1):101–106. https://doi.org/10.2174/15734030308784245810 PMID: 19836284

22. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: A scientific statement from the American Heart Association. Circulation 2012; 126(24):2890–2909. https://doi.org/10.1161/CIR.0b013e318276f86cb PMID: 23159553

23. Al-Qaisi M, Nott DM, King DH, Kadouora S. Ankle brachial pressure index (ABPI): An update for practitioners. Vasc Health Risk Manag 2009; 5(1):833–841. https://doi.org/10.2147/vhrm.s6759 PMID: 19851521

24. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: A scientific statement from the American Heart Association. Circulation 2017; 11(10):359–409.

25. Marius RA, Iliuta L, Guberna SM, Sinescu C. The role of ankle-brachial index for predicting peripheral arterial disease. Maedica 2014; (9):293–302. PMID: 25705296

26. Isahq M, Khan GJ, Zulfiqar S. Role of ankle brachial index in the diagnosis of peripheral artery disease. Gomal J Med Sci 2012; 10(1):97–103.

27. Ali FA, Memon AS, Iqbal A. Relationship of ankle brachial index with age, body mass index, smoking and lipid profile. Pakistan J Med Sci 2012; (3):536–540.

28. Kanda E, Ai M, Okazaki M, Maeda Y, Sasaki S, Yoshida M. The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level. BMC Nephrol 2013; 14(1):144–186. https://doi.org/10.1186/1471-2369-14-212 PMID: 24093487

29. Sigvant B, Wiberg-hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007; 45(6):1185–1191. https://doi.org/10.1016/j.jvs.2007.02.004 PMID: 17543683

30. Atiku S, Ayomide F, Olaniyi O, Thaddeus J, Oyebola A. What we know about Lagos State Finances. Lagos State Data Book 2018; 1–30.
31. Ephraim R, Brenyah R, Osei F, Anto E, Basing A, Darkwah K. Demographic, clinical and therapeutic characteristics of children aged 0–15 years with nephrotic syndrome: A retrospective study of the Komfo Anokye demographic, clinical and therapeutic characteristics of children aged 0–15 years with nephrotic syndrome. Asian J Med Heal 2017; 5(2):1–9.

32. Lane JC. Paediatric nephrotic syndrome. [Internet]. 2020 [Cited 2021 May 9] Available from: https://emedicine.medscape.com/article/982920-overview, e-Medicine from WebMD.

33. Kliegman R, Behrman R, Jenson H, Stanton B. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: Elsevier Saunders 2007. 354–490.

34. Chin-Fu W, Yu-Tsun S, Kai-Sheng H. Reference values of brachial-ankle pulse wave velocity in children. Pediatr Cardiol 2008; 28(1):35–38.

35. Yiming G, Zhou X, Lv W, Peng Y, Zhang W, Cheng X, et al. Reference values of brachial-ankle pulse wave velocity according to age and blood pressure in a central Asia population. PLOS ONE 2017; 12(4):1–12.

36. Keppy N, Bain G, Allen MW. Enzymatic colorimetric methods for the analysis of human serum cholesterol by UV-visible spectroscopy. Thermo Fisher Scientific 2009; 20(6):1–2.

37. Mcgowan MW, Aloysius JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983; 29(3):54–58. PMID: 6825269

38. Garrido-miguél M, Notario-pacheco B. Diagnostic accuracy study of an oscillometric ankle-brachial index in peripheral arterial disease: The influence of oscillometric errors and calcified legs. PLOS ONE 2016; 11(11):1–16. https://doi.org/10.1371/journal.pone.0167408 PMID: 27898734

39. Paquissi F, Arminda B, Paquissi C, Almeida B. Prevalence of peripheral arterial disease among adult patients attending outpatient clinic at a general hospital in South Angola. Scientifica 2016; 6(1):1–7.

40. Ohanian J, Liao A, Forman SP, Ohanian V. Age related remodelling of small arteries is accompanied by increased sphingomyelinase activity and accumulation of long-chain ceramides. Physiol Rep 2014; 2(5):148–156.

41. Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, et al. High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan. Clin Exp Neprol 2017; 21(4):651–657. https://doi.org/10.1016/s10157-016-1319-z PMID: 27590892

42. Yeboah K, Pupampu P, Yorke E, Antwi DA, Gyan B, Amoah AG. Body composition and ankle-brachial index in Ghanians with asymptomatic peripheral arterial disease in a tertiary hospital. BMC Obes 2016; 3(27):1–8.

43. Fowkes GR, Aboyans V, Fowkes F, Mc Dermott MM, Samson UK, Criqui MH. Peripheral arterial disease: epidemiology and global perspectives. Nat Rev Cardiol 2017; 14(3):156–170. https://doi.org/10.1038/nrcardio.2016.179 PMID: 27853158

44. Willenberg T, Diehm N, Zwahlen M, Kalka C, Do DD, Gretener S, et al. Impact of long term corticosteroid therapy on the distribution pattern of lower limb atherosclerosis. Eur Journal Vasc Endovasc Surg 2010, 39(4):441–446.

45. Whitworth JA, Harrinon JT, Kassirer JP. Mechanisms of glucocorticoid induced hypertension. Kidney Int 1987; 31(1):1213–1224. https://doi.org/10.1038/ki.1987.131 PMID: 3298796

46. Martha UE, Andrew E, Osemwingie OA. Hypertension and lower extremity peripheral arterial disease: An overlooked association. Nig J Cardiol 2013; 10(1):26.

47. Umueri EM, Obasohan AO. Obesity indices and peripheral artery disease measured by ankle brachial index in Nigerian out patients. West Afr J Med 2018; 35(1):3–8. PMID: 29607437

48. Klein S, Allison DB, Heymsfield SB, Kelly DE, Leibel RL, Nonas C, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health. Diabetes Care 2007; 30(6):1647–1652. https://doi.org/10.2337/dc07-0921 PMID: 17360974

49. Onat A, Avci GS, Barlan MM, Uyarci H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28(8):1018–1025. https://doi.org/10.1038/sj.ijo.0802695 PMID: 15197408

50. Savvas C, Tornaritis M, Savva ME, Kourides Y, Panagi A, Stilkiotou N, et al. Waist circumference and waist to hip ratio are better predictors of cardiovascular disease risk factors in children than body mass index. Int J Obesity 2000; 24(11):1453–1458.

51. Simmonds J, Grundy N, Trompeter R, Tullius K. Long term steroid treatment and growth: A study in steroid dependent nephrotic syndrome. Arch Dis Child 2010; 95(2):146–149. https://doi.org/10.1136/adc.2007.129957 PMID: 20172895

52. Linton MR, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, et al. Role of lipids and lipoproteins in atherosclerosis. Endotex Res 2019; 40(1):30–35.
53. Adu BM. Serum lipid profile abnormalities among patients with nephrotic syndrome. Int J Med Biomed Res 2013; 2(1):13–17.

54. Adekoya AO, Adekoya BJ, Desalu OO, Aderibigbe A. Pattern of lipid profile in adult nephrotic syndrome patients in Nigeria. Int J Med Biomed Res 2011; 2(4):954–960.

55. Tsai HJ, Huang JC, Tsai YC, Chen Li, Chen SC, Chang JM, et al. Association between albumin, C-reactive protein and ankle brachial index in haemodialysis. Int J Nephrol 2018; 23(4):110–111.